Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
Enhertu is the first breast cancer treatment NICE has been unable to recommend for 6 years and breaks a line of 21 positive breast cancer recommendations. This includes the positive recommendation in February for Talazoparib (Talzenna) for treating HER2 negative locally advanced or metastatic breast cancer.
